期刊文献+

减肥药作用途径的拓展与临床应用评价 被引量:1

Research Progress in Expansion of Modes of Action of Fat-reducing Agents and Evaluation of the Clinical Application
在线阅读 下载PDF
导出
摘要 目的 :为临床合理应用减肥药提供参考。方法 :综合近年来国内、外文献进行分析、评价。结果与结论 :减肥药研究进展十分迅速 ,作用途径不断拓展 。 OBJECTIVE:To provide information for rational use of fat-reducing agents METHODS:To collect,analyse and evaluate the relevant data reported in literature RESULTS & CONCLUSION:The research of fat-reducing agent advances rapidly and the modes of action of these agents steadily expand which displays a good prospects in therapeutic efficacy
作者 张石革 臧靖
机构地区 北京积水潭医院
出处 《中国医院用药评价与分析》 2002年第2期84-86,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 减肥药 临床应用 合理用药 研究进展 食欲抑制剂 混合型食欲抑制剂 fat-reducing agent progress clinical application evaluation
  • 相关文献

参考文献15

  • 1周予昭,黄仲义.减肥药的现状与评价[J].中国药房,2000,11(4):168-169. 被引量:9
  • 2张建功,程桦.肥胖症药物治疗进展[J].国外医学(内科学分册),2000,27(2):47-51. 被引量:6
  • 3左晓春,笪宏远.新一代减肥药──西布曲明[J].中国临床药理学杂志,2000,16(2):155-157. 被引量:27
  • 4Lean ME .Sibutramine areview of clinical efficacy[J].International Journal of Obesity, 1997,21(Suppl 1) :30.
  • 5Melian AT,Zhi J ,Zelasko R,et al .The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers[J ] . Eur J Clin Pharmacol, 1998,54(9) :733.
  • 6魏桂林,朱珠.减肥新药——奥利司他[J].中国医药导刊,2000,2(3):53-53. 被引量:5
  • 7Zhi J ,Melia AT,Eggers H,et al .Review of limited systemic absorption of orlistat,a lipase inhibitor in healthy human volunteers[J ] .J Clin Pharmacol, 1995,35:1 103.
  • 8Van Gaal LF,Broom IJ ,Enzi G,et al.Efficacy and tolerability of orlistat in the treatment of obesity:a 6 month dose ranging study[J ] .Eur J Clin Pharmacol, 1998,54(2): 125.
  • 9刘萍,边强.肥胖症治疗的新途径[J].国外医药(合成药.生化药.制剂分册),2000,21(1):13-14. 被引量:6
  • 10Schaffhawser AO,Striker A,Brumer L,et al.Study on efficacy of NPY in animals[J ] .Diabetes, 1997,46(11):1 792.

二级参考文献20

  • 1沈稚舟 陈灏珠.肥胖症.实用内科学(第10版)[M].北京:人民卫生出版社,1997.872.
  • 2章鸣.早期研究开发中的新减肥药[J].国外药讯,1998,10(9):41-41.
  • 3A. T. Melia,J. Zhi,R. Zelasko,D. Hartmann,C. Güzelhan,R. Guerciolini,J. Odink.The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers[J].European Journal of Clinical Pharmacology (-).1998(9-10)
  • 4L. F. Van Gaal,J. I. Broom,G. Enzi,H. Toplak.Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study[J].European Journal of Clinical Pharmacology.1998(2)
  • 5Hollander PA,Elbein SC,Hirsch IB,et al.Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes[].Diabetes Care.1998
  • 6Sjostrom L,McCarthy WJ,Lekkerkerker.Orlistat and weight loss (letter)[].The Lancet.1998
  • 7Bray GA.Obesity: a time bomb to be defused[].The Lancet.1998
  • 8Sjostrom L,Rissanen Aila,Andersen T,et al.Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients[].The Lancet.1998
  • 9Davidson MH,Hauptman J,DiGirolamo M,et al.Weight control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat[].The Journal of The American Medical Association.1999
  • 10Garratt CJ,Hind ID,Haddock RE.Single/repeat dose kinetics ofsibutramine metabolites in obeses subjects (abstract)[].Journal of Clinical Pharmacology.1995

共引文献48

同被引文献29

  • 1陈希.减肥药物的研究进展及前景[J].海峡药学,2004,16(4):8-11. 被引量:3
  • 2小川佳宏,赵美眯.减肥药的现状[J].日本医学介绍,2005,26(8):367-369. 被引量:3
  • 3黄世杰.由于致癌危险美国消协要求奥利司他撤出市场[J].国外医学(药学分册),2006,33(5):328-328. 被引量:6
  • 4Zhi J, Mulligan TE, Hauptman JB. Long - term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients[ J]. J Clin Pharmacol, 1999,39 ( 1 ) :41 - 46.
  • 5Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obesesubjects treated for 2 years with orlistat : a randomized controlled trial[ J]. JAMA 1999,281 ( 3 ) :235 - 242.
  • 6Bray GA, Greenway FL. Current and potential drugs for treatment of obesity[ J]. Endocr Rev,1999,20(6) :805 -875.
  • 7Finer N, James WP, Kopelman PG, et al. One year treatment of obesity : a randomized, double blind, placebo controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor [ J ]. Int J Obes Relat Metab Disord, 2000,24(3) : 306 -313.
  • 8杨世享.口服降糖药一阿卡波糖.中国药学杂志,1998,33(4):246-247.
  • 9Lorenzi M, Montisano DF,Toledo S. High glucose induces DNA damage in cultured human endothelial cell[J].J Clininvest, 1986, 77:322.
  • 10Kcman WN, Viscoh CM, Brass LM, et al. Phenlpropanolamie and the risk of hemorrhagic stroke [ J ]. New Eng J Med,2000,343 ( 25 ) : 1826 - 1832.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部